Wenrui Xie

Prof. Dr. Wenrui Xie


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
DHDong-Ni Huang
Dong-Ni Huang
HZHao-Jie Zhong
Hao-Jie Zhong
YCYing-Li Cai
Ying-Li Cai
WXWenrui Xie
Wenrui Xie
XHXing-Xiang He
Xing-Xiang He
Background. Acute pancreatitis (AP) is a common and potentially life-threatening inflammatory disease that can cause various complications, including systemic inflammatory response syndrome (SIRS), pleural effusion, ascitic fluid, myocardial infarction, and acute kidney injury (AKI). However, there is still a lack of rapid and effective indicators to assess the disease. The aim of this study was to investigate the associations of high serum lactate dehydrogenase (LDH) levels with AP severity and systemic complications. Methods. AP patients treated from July 2014 to December 2020 were retrospectively enrolled. They were divided into elevated ( ) and normal ( ) LDH groups. Their demographic data, clinical data, hospital duration, and hospital expenses were analyzed. Linear and binary logistic regression analyses were used to determine whether elevated LDH is a risk factor for AP severity and complications after adjusting for confounders. Results. There were significant differences in AP severity scores (Ranson, MODS, BISAP, APACHE II, and CTSI), hospital duration, hospital expenses, and the incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI) between the elevated and normal LDH groups. After adjusting for confounders, elevated LDH was associated with AP severity scores and hospital duration and expenses (based on linear regression analyses) and was a risk factor for the occurrence of AP complications and interventions, that is, diuretic and vasoactive agent use (based on binary logistic regression analyses). Conclusions. Elevated LDH is associated with high AP severity scores and high incidences of complications (SIRS, pleural effusion, ascitic fluid, myocardial infarction, and AKI).

19 May 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
YHYanhui Huang
Yanhui Huang
JHJiayuan Huang
Jiayuan Huang
YLYuange Li
Yuange Li
TXTianyu Xu
Tianyu Xu
GQGuoqiao Quan
Guoqiao Quan
WXWenrui Xie
Wenrui Xie
This report presents the first documented application of fecal microbiota transplantation (FMT) for the management of extensive multi-food intolerance involving 52 specific foods in a pediatric patient with autism spectrum disorder (ASD). A 7 years-old autistic child was diagnosed with food intolerance to 52 items, presenting with generalized rashes, diarrhea, and malnutrition (BMI of 12.9) upon exposure or ingestion of the implicated foods. The child received oral fecal microbiota capsule treatment, with a daily dose of nine capsules (a total of 120 capsules per course) for two consecutive treatment courses. The rashes resolved, the child regained tolerance to previously intolerable foods, nutritional status improved, and stool consistency normalized. This case suggests that FMT may hold therapeutic potential for managing food intolerance in autistic patients.

1 April 2023 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
YLYun-Fang Liang
Yun-Fang Liang
SWSi-Qi Wang
Si-Qi Wang
ZPZhao-Yu Pan
Zhao-Yu Pan
ZDZhi-He Deng
Zhi-He Deng
WXWenrui Xie
Wenrui Xie
Background: The prognosis of and occurrence of complications in patients with different clinical features of cirrhosis differ, and cirrhosis with different etiologies has varying clinical characteristics. The aim of this study was to describe the liver function markers, hepatic complications, and psychological features differentiating patients with hepatitis B virus (HBV) infection-related and alcohol-related cirrhosis. Materials and Methods: This was a retrospective and observational study that analyzed the medical data of inpatients with alcohol-related or HBV infection-related cirrhosis from May 2014 to May 2020. Markers of liver function, portal hypertension, and psychological symptoms were compared between the two groups. Results: Patients with alcohol-related cirrhosis showed higher Self-Rating Anxiety Scale scores and prevalence of hypoproteinemia, fatty liver, and depression than those with HBV infection-related cirrhosis (all P < 0.05). After adjustment for potential confounders, patients with alcohol-related cirrhosis also showed higher risks of increased total cholesterol (odds ratio [OR] =2.671, 95% confidence interval [CI]: 1.160–6.151, P = 0.021), increased high-density lipoprotein-cholesterol (OR = 2.714, 95% CI: 1.009–7.299, P = 0.048), and fatty liver (OR = 2.713, 95% CI: 1.002–7.215, P = 0.048); however, splenomegaly and splenectomy were significantly associated with HBV infection-related cirrhosis (OR = 2.320, 95% CI: 1.066–5.050, P = 0.034). Conclusion: Patients with alcohol-related cirrhosis were more likely to develop hyperlipidemia, fatty liver, and psychological symptoms, whereas those with HBV-related cirrhosis had a higher risk of splenomegaly.

16 October 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JHJiayuan Huang
Jiayuan Huang
TXTianyu Xu
Tianyu Xu
GQGuoqiao Quan
Guoqiao Quan
YLYuange Li
Yuange Li
XYXiaoya Yang
Xiaoya Yang
WXWenrui Xie
Wenrui Xie
Acute liver failure (ALF), associated with a clinical fatality rate exceeding 80%, is characterized by severe liver damage resulting from various factors in the absence of pre-existing liver disease. The role of microbiota in the progression of diverse liver diseases, including ALF, has been increasingly recognized, with the interactions between the microbiota and the host significantly influencing both disease onset and progression. Despite growing interest in the microbiological aspects of ALF, comprehensive reviews remain limited. This review critically examines the mechanisms and efficacy of microbiota-based treatments for ALF, focusing on their role in prevention, treatment, and prognosis over the past decade.

29 August 2026 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
XYXiaoya Yang
Xiaoya Yang
JHJiayuan Huang
Jiayuan Huang
LWLei Wu
Lei Wu
TXTianyu Xu
Tianyu Xu
GQGuoqiao Quan
Guoqiao Quan
WXWenrui Xie
Wenrui Xie